Revista de psiquiatría y salud mental

• 

  Año 2022, Vol. 15, Número 4

  • Editorial

    • Here we go again! Subtyping diagnosis and refining treatments

      Javier Vázquez Bourgon

      págs. 221-222

      

  • Originales

    • Risk factors of deficit and non-deficit schizophrenia: Results from a cross-sectional study

      Agnieszka Cyran, Patryk Piotrowski, Jerzy Samochowiec, Tomasz Grąźlewski, Błażej Misiak

      • Resumen

      págs. 223-229

      

    • Dried Blood Spot (DBS) as a useful tool to improve clozapine, aripiprazole and paliperidone treatment: From adherence to efficiency

      Miquel Bernardo Arroyo, Gisela Mezquida Mateos, Paula Ferré, Bibiana Cabrera Llorca, Mercè Torra, Ana Maria Lizana, Mercè Brunet

      págs. 230-237

      

    • Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries

      Carlos de las Cuevas Castresana, Emilio José Sanz Álvarez, Can-Jun Ruan, José de León

      págs. 238-250

      

    • Clinical symptoms and social functioning in schizophrenia

      María José Escandell, Gemma Prat, Mar García Franco, José Ramón Martín Martínez, Susana Ochoa Güerre, Ingrid Tortades, Sonia Vilamala, Marina Verdaguer Rodríguez, Emma Casas Anguera

      págs. 251-258

      

    • Different measures for auditory hallucinations in populations with psychosis. The Validation of the Spanish versions of the Auditory Vocal Hallucination Rating Scale (AVHRS) and the Positive and Useful Voices Inquiry (PUVI)

      Esther Lorente Rovira, Eva María Grasa, Susana Ochoa Güerre, Iluminada Corripio Collado, Trinidad Peláez, Raquel López Carrilero, Ángela Gutiérrez Gea, María Morano Guillén, José María Villagrán Moreno, Agna A. Bartels Velthuis, Jack A. Jenner, Julio Sanjuán Arias

      págs. 259-271

      

    • Estabilidad diagnóstica en la psicosis inducida por sustancias

      Lucia Inchausti Lopez de Larrucea, Iñigo Gorostiza Ormaetxe, Miguel Ángel González Torres, Rodrigo Oraá Gil

      págs. 272-280

      

    • Valproate, obesity and other causes of clozapine poor metabolism in the context of rapid titration may explain clozapine-induced myocarditis: A re-analysis of a Turkish case series

      Aygün Ertuğrul, A. Elif Anıl Yağcıoğlu, Esen Ağaoğlu, Ahmet Alp Karakaşlı, Sertaç Ak, M. Kâzım Yazıcı, José de León

      págs. 281-286

      

  • Cartas al director

    • Clozapine for the treatment of pediatric encephalopathy associated with nonketotic hyperglycinemia

      Sara Jiménez Fernández, Manuel Gurpegui Fernández de Legaria, José de León, Luis Gutiérrez Rojas

      págs. 287-289

      

    • A Covid-19 outbreak in a Spanish long-term psychiatric hospital led to infections in 6 clozapine patients: elevations in their plasma clozapine levels

      Manuel Arrojo Romero, Maria Rosario Codesido Barcala, José de León

      págs. 290-292

      

    • A clozapine's uncharted voyage: Five years and a pandemic after the end of mandatory haematological notifications to the Spanish medicines agency

      Pilar Andrés Olivera, María Concepción Turrión Aznar, Emilio Fernández-Egea, Jesús Pérez Sánchez Toledo

      págs. 293-294

      

    • Clozapine-induced myocarditis in Russia: Animal studies but no clinical studies

      Oleg O. Kirilochev, Carlos de las Cuevas Castresana, José de León

      págs. 294-295